Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03215992 · ClinicalTrials.gov registry record · NA
Optical Tomography in Prostate Cancer
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT03215992: Completed NA study, sponsored by Columbia University.
NCT03215992 is a NA study that has completed, run by Columbia University. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03215992, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is looking to see if a new device, diffuse optical tomography (DOT), can detect prostate cancer. The investigators will also see if DOT can tell the difference between high risk and low risk prostate cancers.
Primary Outcome
Total number of subjects who produce usable images will be measured to assess feasibility of concurrent transrectal ultrasound guided (TRUS) biopsy/DOT imaging, which is defined as successfully imaging and generating usable DOT data in 60% of subjects.
Interventions
- DEVICE Diffuse Optical Tomography (DOT) System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-06-13 |
| Est. Completion | 2018-02-08 |
| Phase | NA |
What the finished NCT03215992 record still lists
NCT03215992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Diffuse Optical Tomography (DOT) System is the first listed.
NCT03215992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03215992 about?
NCT03215992 is a clinical study titled "Optical Tomography in Prostate Cancer". This study is looking to see if a new device, diffuse optical tomography (DOT), can detect prostate cancer. The investigators will also see if DOT can tell the difference between high risk and low risk prostate cancers.
What is the current status of trial NCT03215992?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2016-06-13. Estimated completion is 2018-02-08.
What interventions are being tested in trial NCT03215992?
The interventions under investigation include: Diffuse Optical Tomography (DOT) System (DEVICE).
Who is sponsoring clinical trial NCT03215992?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03215992's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI